Human trial

Tirzepatide

Type 2 diabetes and obesity in large, published randomized trials.

A 15-second vertical explainer plays in this frame when the file is published.

What it is

Tirzepatide is a dual incretin medicine that acts on GLP-1 and GIP pathways. It is a prescription peptide medicine with large published trials in type 2 diabetes and obesity. Brand names people may have seen include Mounjaro and Zepbound. We do not prescribe it or sell it.

Studied for

  • Type 2 diabetes, in large published randomized trials.
  • Obesity, in large published randomized trials.
  • Gut–brain signaling through GLP-1 and GIP pathways.

The evidence

Human trial. In this library it sits with semaglutide: large, published randomized trials, not animal-only research and not an anecdote. We are not ranking it against semaglutide. Both have a formal human-trial record, and a prescriber is who compares them for a real person.

What this page will not do

  • A published trial is not a suggestion that you should take it.
  • We do not give doses or switching schedules.
  • Approved uses are specific. Confirm the current label.

Still open

  • Which incretin medicine, if any, belongs in a particular care plan.
  • How trade-offs described in the trials apply outside a study population.

Educational content only. This page does not diagnose, treat, cure, or prevent anything, and it is not a dose. Talk with a licensed physician before starting, stopping, or changing any medication. Library reviewed November 2026.